We are a team of entrepreneurs, scientists, researchers and tech developers who are all passionate about bringing innovation in digital health to patients. We have built Dopavision to develop breakthrough digital healthcare solutions, combining scientific and technical curiosity with the goal of creating significant benefits for patients. Our offices are located in the heart of Berlin.
Myopia, or shortsightedness, is a condition where the visual image is focused in front of the retina, instead of on the retina itself, as it should. People with myopia have good near sight vision but poor distance vision. Dopavision is developing a digital therapeutic for myopia which can be seamlessly and invisibly integrated with the use of a smartphone. Myopia is a visual condition that affects on average every third person globally, a share that has increased rapidly during the last two decades. It has grown to alarming proportions in Asia where prevalence rates, e.g., in Singapore, have reached 80% among young adults. High myopia imposes a significant risk to cause visual impairment and even blindness later in life.
Total Funding: €13,200,000
Funding Stage: Series A
Business Stage: Scaling Up
Market: B2B
Company Size: 1 to 25
Founded: 2017
For AI/ML Startup Founders
Get introduced to VC/PE/CVC investors
For Investors at VC/PE firms
Get introduced to AI/ML Startup founders or founders at Dopavision